BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) Shares Jump on Insurance Coverage for Fat Pills


11/21/2012 12:37:51 PM

Health insurer Aetna Inc (AET.N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up. The decision by the third-largest health insurer to provide coverage for Vivus' Qsymia and Arena's Belviq may boost adoption of the diet pills. "This is probably the simplest business decision on their plate in all of 2012, because to not reimburse this would have put them in the crosshairs of every single healthcare decision maker in the United States," WBB Securities LLC analyst Stephen Brozak said. "Everyone acknowledges that we have a pandemic obesity problem, and to not be a part of a solution even if its a marginal solution, means you are part of the problem," he added. Vivus faced problems as it reported lackluster initial sales of Qsymia earlier this month, citing a lack of reimbursement coverage. Chief commercial officer Mike Miller said on a post-earnings conference call on November 6 that about 30 percent of patients chose not to fill after receiving Qsymia prescription due to cash outlay.

Read at Reuters
Read at The Street.com
Read at Seeking Alpha
Read at CBS News


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->